A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Volunteers

Inclusion Criteria:

- Volunteers with Body Mass Index (BMI) 18-34 kilograms per meter square (kg/m^2),
inclusive

- Male volunteers who are willing to use barrier contraception for the duration of the
study and for 3 months following the end of treatment

- Female volunteers who are of non-child bearing potential

- Female volunteers who are of child bearing potential utilizing two effective methods
of contraception for the duration of the study and for 3 months following the end of
treatment

Exclusion Criteria:

- Evidence of clinically significant disease or disorder (e.g., renal, cardiac,
bronchopulmonary)

- Any other condition or disease which would place the volunteer at undue risk, or
interfere with the assessment, or with the ability of the volunteer to complete the
study

- Clinically significant orthostatic hypotension present at screening or history of
clinically significant hypotensive episodes or symptoms of fainting, dizziness, or
lightheadedness.

- Volunteers with abnormal electrocardiogram (ECG), bradycardia or mean QTc at
screening

- Positive result for Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV) 1 or
2 at screening

- Renal impairment

- Transplant recipients

- A known clinically relevant history of allergy or hypersensitivity

- Any clinically relevant abnormal laboratory test results

- A clinically relevant history of abuse of alcohol or other drugs of abuse

- Any major illness within 30 days prior to the screening examination

- Smoking of more than 10 cigarettes a day or an equivalent amount of tobacco in the
form of cigars or pipe

- Participation in a clinical study with an investigational drug within 3 months prior
to Day 1

- Donation/loss of more than 500 milliliters (mL) of blood within 3 months prior to Day
1

- Positive pregnancy test at screening or Day -1 and lactating women